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tion can be considered to be a very cost-effective strategy
when used to prevent progression of AMD.
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LOW VISUAL ACUITY AND BLINDNESS SOCIAL
COSTS IN FRANCE
Lafuma A1, Pradet S1, Berdeaux G2
1Cemka, Bourg-La-Reine, France; 2Alcon, Rueil-Malmaison,
France
OBJECTIVES: To estimate disability pension costs and
institutionalisation associated with low visual acuity
(LVA) and blindness in France. METHODS: Two
national surveys performed by INSEE (Institut National
de la Statistique et des Etudes Economiques) on disabil-
ity and institutionalisation in France (1998–1999) were
carried out. Information (socio-demographics, disability
reasons, disability pension and type of institution) was
collected on two national representative samples of living
at home and institutionalised populations. Three groups
were identiﬁed in each case: blind people, LVA people and
a control group (non-blind/LVA general population).
Linear regression was used to adjust the group pension
differences for gender, age and professional categories.
The probability of being institutionalised due to blind-
ness/LVA when >55 was estimated with Bayesian rules.
RESULTS: 15,288 people were included in the survey of
institutionalised persons; 279 were blind and 2,536 had
LVA. The control group included more women. The blind
were younger while those with LVA were older; the blind
had fewer jobs. 16,915 people were included in the living
at home survey; 86 were blind and 1,080 had LVA. The
control group had more women and was younger, while
those with LVA had less skilled jobs. Disability pensions
varied with gender, age and professional categories. Insti-
tutionalised blind people received €112.64 per month
more than the control group and €484.33 more than
people living at home. Figures for LVA patients were
respectively €19.22 and €201.52. Probability of being
institutionalised was 6.13% for blind people, 5.91% for
LVA and 1.14% for the control group. A person has a 5.4
times greater chance of being institutionalised if blind and
5.2 times with LVA. CONCLUSION: Blindness and LVA
lead to additional disability pensions payments and insti-
tutionalisation. Medical programs aimed at delaying
blindness or LVA may have economic consequences
outside the direct medical costs that should be taken into
account.
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OBJECTIVES: To assess cost-effectiveness and cost-
utility ratios of a new anti-allergic agent Olopatadine in
comparison to the reference treatment, Levocabastine, 
in Seasonal Allergic Conjunctivitis (SAC) in France,
Germany, Italy, Spain, Sweden and the United Kingdom.
METHODS: Data from a randomized, double-blind clin-
ical trial of Olopatadine (O) versus Levocabastine (L) in
SAC were used in the analysis. A total of 210 patients
were randomized (O:101, L:109). Ocular symptoms 
and investigator’s Clinical Global Impression (CGI) were
reported at baseline and at days 7, 14, 30 and 42. Fac-
torial analysis techniques were used to derive a synthetic
symptoms score (effectiveness score) from multi-
dimensional symptom scales. In order to transform symp-
toms scores into utility scores, a panel of 32 ophthal-
mologists was interviewed in the 6 European countries to
collect data on the painfulness of various symptomatic
statuses. Curves representing the evolution of effective-
ness and utility scores over time were projected from 42
to 90 days, assuming 3 types of treatment effects after day
42, namely, a maintained effect (H1), a catch-up on com-
paritor (H2) and no additional effect (H3). Areas under
effectiveness and utility curves (AUCs) were computed in
both arms. Olopatadine-Levocabastine differentials were
respectively represented in the effectiveness criterion as
the number of Symptoms Adjusted Days saved, (SAD)
and in the utility criterion as the number of Quality
Adjusted Days saved, (QAD). RESULTS: Olopatadine
showed a gain from 1.3 (H3) to 2.3 (H1) SADs, and from
0.8 (H3, UK) to 4.2 (H1, Germany) QADs, over 3
months. Assuming a 20% higher price for Olopatadine
compared to Levocabastine, the incremental cost-
effectiveness ratios of Olopatadine ranged from €1.27
(H1, France) to €21.3 (H3, Italy) per SAD saved, while
incremental cost-utility ratio ranged from €1.06 to €23.4
per QAD saved. CONCLUSION: Olopatadine showed
reasonable cost-effectiveness and cost-utility ratios versus
Levocabastine in the treatment of SAC for 6 European
countries.
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PHARMACOECONOMIC EVALUATION OF A
NEW TWO COMPOUND OINTMENT
(DAIVOBET®) AND CALCIPOTRIOL
(DAIVONEX®) IN THE TREATMENT OF
PSORIASIS VULGARIS IN SWEDEN
Sørensen M, Nørregaard J
LEO Pharma, Ballerup, Denmark
OBJECTIVES: The objective of the study is to investigate
the cost-effectiveness of treating patients with psoriasis
vulgaris in Sweden. METHODS: The cost-effectiveness
analysis was performed by comparing effectiveness data
obtained from an international multicentre study with the
cost of the two products. RESULTS: The expected cost
per percentage reduction in PASI in Sweden is SEK 15.78
for TCP twice daily, followed by SEK 8.98 for cal-
cipotriol, and TCP once daily SEK 8.29 when comparing
